Private Market View

Perceptyne

Hyderabad, India · Founded 2021 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$3.3M
Last round

Key facts

  • It has raised $3.3M; the latest was Seed Round ($3.0M) in Oct 2024.
  • Notable investors include T-Hub, Venture Catalysts, z21 Ventures, Whiteboard Capital, Aditya Damani14 tracked in total.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 14 names
  • ·Watchlist + deal alerts for Perceptyne
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Perceptyne are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Perceptyne

Developer of multi-utility robotic arms designed for the automation of tasks. The company's products have many features, including three-dimensional image sensors, articulated hands with in-built actuators, and AI-enabled tactile sensing that can be used for product assembly, kitchen automation, packing, and machine tending, enabling businesses to get a dual-arm robot that can achieve human-like functionality at an affordable cost.

Sector
Information Technology
HQ
Hyderabad, India
Founded
2021
Employees
33
Ownership
Privately Held (backing)
PA Mark — not yet priced

Perceptyne doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Perceptyne shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Perceptyne in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.